BioCurex, Inc.(fka BOCX)

[Gold Seeker]

LT, biocurex is not in trouble just because of Smithline. The inability to pay the loan is just a symptom that the technology is not viable. If Abbott thought RECAF had value, they would have proceeded and the loan would not be a problem.

If Abbott had taken RECAF into trials, do you really think that the stock would be selling for ten cents? Do you think investors would be facing massive dilution?

If RECAF was viable as a commercial test, do you not think that cancer organizations would not be praising the expected value of being tested? None of this is happening. The only people you find hyping the value of RECAF are a few current investors, stock promoters and Moro.